Abstract
BackgroundThe results of the first randomized controlled trial comparing cyclophosphamide (CYC) and mycophenolate (MMF) for systemic sclerosis-related interstitial lung disease (SSc-ILD) demonstrated that MMF had improved safety and tolerability profiles...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
